Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 20, 2005. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific share transactions and does not contain financial performance data.
Material Changes
The only material change reported is a transaction involving the GlaxoSmithKline Employee Trust ("the GSK Trust"). On January 19, 2005, Abacus (GSK) Trustees Limited transferred 570 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Management Commentary and Risks
The filing notes that the GSK Trust is a discretionary trust where all current and former employees are potential beneficiaries. Consequently, three directors—Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe—hold an interest in the shares held by the trust in the same manner as other employees. No other risks, contingencies, or unusual items are disclosed in this text.
Investor Verification Points
- Confirm the total number of shares held by the GSK Trust following the transfer of 570 shares.
- Verify the specific allocation of the 570 shares among the three named directors versus other plan participants.
- Review the full terms of the SmithKline Beecham Employee Share Option Plan 1991 to understand vesting conditions.